Scully Royalty (NYSE:SRL) Azioni

Scully Royalty

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Scully Royalty Ltd

SPDR Blackstone Senior Loan ETF

SEAFIELD RES LTD COM by Seafield Resources., Ltd.

Seafield Resources Ltd

SECURLINX CORP by Securlinx Corp.

STHN REALTY CO CAL by Southern Realty Co.

Southern Realty Co

SALAZAR RESOURCES LTD ORD by Salazar Resources Ltd.

Salazar Resources Ltd

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $30 price target.

News

Price Target

Reiteration

Analyst Ratings

NTLA

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

QBTS

D-Wave Launches Commercial-Grade Advantage2 Quantum System To Tackle Complex Problems In Optimization, AI And Materials Simulation

Biotech

General

TRVI

Trevi Therapeutics Presents Additional Analyses From Phase 2a RIVER Trial At American Thoracic Society 2025 International Conference

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 -
- Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligibility for Priority Review; the BTD request was based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response -
- Biologics License Application (BLA) submission for veligrotug is on track for second half 2025 -
- Actively preparing organization for planned U.S. commercial launch in 2026 -
Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug ("veli"), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye.
The THRIVE phase 3 clinical trial in active TED evaluated 5 infusions of veli or placebo every three weeks with primary topline analysis at week 15 and then followed patients through week 52.

VRDN

Viridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients

Toolstation Selects GXO As Logistics Partner In The Netherlands

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $8 to $3.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $3

-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis –
-- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases –
-- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway –
-- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD --
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jpUKFDUv9SBOaAYEuDBVLMrIuE8vmhtiOpWfbossUQvn_ZgVR_ZhWKlfdYagPXw3J_EzkmVJYc5JjZ7ZCkYRpRxCeF1prBNvXpoYxY6gplo=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD).
This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory. Dr. Lee was the lead author of a landmark 2024 Nature paper that identified ETS2 as a master regulator of inflammatory responses in IBD, and uncovered a novel genetic mechanism behind the disease, which pointed to a new, potentially effective treatment strategy through MEK inhibition.
In this new study RNA sequencing was used to measure gene expression, with PAS-004 consistently outperforming the FDA-approved MEK inhibitor selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1/2 pathway genes. These data suggest more robust and durable MEK inhibition by PAS-004 under inflammatory conditions.

KTTA

Pasithea Therapeutics' New Preclinical Data Shows PAS-004 Provides Superior Inhibition Of ETS2-Driven Inflammatory Responses Compared To Selumetinib In Human Macrophage Model Of Chronic Inflammation In IBD

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) affirms FY2025 sales outlook from $2.00 million-$5.00 million to $2.00 million-$5.00 million.

Guidance

ARBE

Arbe Robotics Affirms FY2025 Sales Guidance of $2.00M-$5.00M

Autozi Regains Nasdaq Compliance As Share Price Meets $1.00 Minimum Bid Requirement Over 14 Consecutive Trading Days

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) reported quarterly losses of $(0.09) per share. This is a 35.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $40.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 60.00 percent. This is a 70.80 percent decrease over sales of $137.00 thousand the same period last year.

Earnings

Earnings Misses

Arbe Robotics Q1 Adj. EPS $(0.09) Up From $(0.14) YoY, Sales $40.00K Miss $100.00K Estimate

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees Q2 sales of $7.000 million-$7.100 million vs $7.17 million analyst estimate.

CRGO

Freightos Sees Q2 Sales $7.000M-$7.100M vs $7.17M Est

Rosenblatt analyst Catharine Trebnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and maintains $235 price target.

PANW

Rosenblatt Maintains Buy on Palo Alto Networks, Maintains $235 Price Target

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) affirms FY2025 sales outlook from $29.00 million-$30.60 million to $29.00 million-$30.60 million vs $29.72 million estimate.

Freightos Affirms FY2025 Sales Guidance of $29.00M-$30.60M vs $29.72M Est

Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 27.27 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $897.06 million which beat the analyst consensus estimate of $842.53 million by 6.47 percent. This is a 24.91 percent increase over sales of $718.15 million the same period last year.

Earnings Beats

Viking Holdings Q1 Adj. EPS $(0.24) Beats $(0.28) Estimate, Sales $897.06M Beat $842.53M Estimate

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $65 price target.

CRSP

HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $65 Price Target

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $6.95 million which beat the analyst consensus estimate of $6.78 million by 2.48 percent. This is a 29.69 percent increase over sales of $5.36 million the same period last year.

Freightos Q1 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $6.95M Beat $6.78M Estimate

Rosenblatt analyst Catharine Trebnick maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Buy and maintains $2.7 price target.

EGHT

Rosenblatt Maintains Buy on 8x8, Maintains $2.7 Price Target

PLTR

Palantir Technologies And Divergent Technologies Partner To Provide Access To Divergent's Advanced Manufacturing Capabilities Via Palantir's Software Platform

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and maintains $340 price target.

Comments

Scully Royalty

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO